Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1, Prospective, Multi-Center, Open-Label, Dose-Escalation Study to Assess the Safety, and Tolerability of EO2002 with and Without Endothelial Brushing or Descemet Stripping in the Treatment of Corneal Edema (EMME-001)

NCT04894110 is registered in ClinicalTrials.gov with Emmecell as lead sponsor.

NCT NCT04894110
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04894110 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1, Prospective, Multi-Center, Open-Label, Dose-Escalation Study to Assess the Safety, and Tolerability of EO2002 with and Without Endothelial Brushing or Descemet Stripping in the Treatment of Corneal Edema (EMME-001)
Lead sponsor
Emmecell
Phase
Phase 1
Overall status
Completed
Start date
June 22, 2021
Completion date
October 3, 2024
Enrollment
42 (actual)
Sites
8

Conditions

As the registry lists them; a condition with its own page is linked.

bullous keratopathy, corneal edema, corneal endothelial dysfunction, corneal endothelial dystrophy, endothelial dysfunction, fuchs dystrophy, fuchs endothelial corneal dystrophy, moderate corneal endothelial decompensation, pseudophakic bullous keratopathy